CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab (BIG 1-01)

Source: Lancet Oncology Area: News Several randomised trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer but have identified CNS as the first site of relapse, possibly because trastuzumab does not adequately penetrate the CNS. To investigate further, researchers used data from the HERA trial to assess the frequency and course of CNS relapses, either as first event or at any time.   The HERA trial (BIG 1-01) is a large randomised phase 3 study comparing treatment with adjuvant trastuzumab after standard adjuvant chemotherapy for 1 year or 2 years with only observation in patients with HER2-positive early breast cancer. The HERA study design, eligibility criteria, randomisation, treatment schedule, and follow-up have been reported previously (see NELM abstract below).   In this CNS-specific analysis, researchers retrospectively gathered information about subsequent CNS recurrence with a data collection form that was circulated to ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news